欧州におけるプロテオミクス技術の市場機会

Abstract

Research Overview

Less than favourable return on investment dissuades potential market entrants

Proteomic research may incur huge capital investment and yield poor revenues for many commercial firms suggesting that there is a required wait period to cross the chasm as in the market lifecycle to see any foreseeable profits. With this uncertainty in the reimbursement climate, proteomic research does not seem to be a welcoming one, as prime applications are perceived in the clinical diagnostics sector. Although Federal ministries are taking measures to aid the companies with some financing for these high risk technology sectors, there is a lot of skepticism prevalent. Notwithstanding the advancements from 2001, coupled with many proteome initiatives happening in Europe, this is viewed as a very promising area of research pursuit, only time holds the keys for the entire proteome to unravel with many technical glitches solved. Pharmaceutical companies are yet too doubtful if they are prepared to adopt the new technology into their drug development pipeline and most importantly companies are wary of the premium pricing that tags along with the many fold advantages.

Technology furthers innovation, one of the principal factors that propel the proteomics market forward

Proteomics measures qualitative and quantitative changes in protein content in a tissue in response to a disease or treatment by scoring the protein-protein interactions. Technology advancements to the classical protein separation technologies, two-dimensional gel electrophoresis remain an ubiquitous approach to assess differential protein expressions. As the tools for expression proteomics find maximum utility in the target discovery phase of the drug development pipeline, it can be reasonable to expect that with technical improvisations, low abundant proteins with poor expression levels can be reliably separated and identified.

The developments of MALDI and ESI technologies have enlarged the scope of building more versatile mass spectrometers that is virtually the cornerstone technology in proteomics, with enhanced facilities of automation and compatibility with other proteomics equipment. The other trend, as suggested by respondents is the emergence of newer dyes is increasing chances for improved sensitivity. Technology advancements have been witnessing huge growth year on year and Frost & Sullivan reckons that by 2011, with more emphasis on high-throughput approach, nanotechnologies and microfluidics coupled with the rapid growing mass spectrometry sector will take proteomics to a newer dimension and boost revenues for the instrument sector.

Public-private partnership to foster new applications using proteomics

A comprehensive evaluation of the technology and service portfolios may need to be realised by suppliers (Tiers 2-3) to gain market presence. The current trend in the market has pointed towards the formation of broad partnerships. It has dawned on many commercial sectors that this is one of the best ways of maximising opportunities in this area as smaller companies can affiliate themselves with larger, more recognised suppliers. Suitable company policies and strategies are likely to increase the probability of achieving success in this highly dynamic market. The other important collaboration is between companies and academic research units. Such alliances are likely to be potentially very interesting, since they are anticipated to be a merger of disciplines, whereby academic research develops groundbreaking research methodologies whilst companies can introduce the technology into possible applications that are likely to boost their business in terms of revenues. With the current emphasis focused towards small and medium enterprise initiatives and towards knowledge transfer programmes by all national public research funding bodies and the European Commission, drug discovery companies should maximize their chances to foster more projects in proteome research and bring it up to speed on the commercial scale. In this way, public research funding institutions can be anticipated to drive the uptake of proteomics tools in the near future.

Table of Contents

• 1. Executive Summary
  • 1. Industry Snapshot
    • 1. Executive Summary
• 2. Glossary
  • 1. Glossary of Terms
    • 1. Glossary
  • 2. Exchange Rates
    • 1. Exchange Rates
• 3. Total Market
  • 1. Market Overview
    • 1. Market Overview and Definition
  • 2. Segmentation
    • 1. Segmentation
  • 3. Market Engineering Measurements
    • 1. Market Engineering Measurements
  • 4. Market Drivers
    • 1. Drivers
  • 5. Industry Challenges
    • 1. Industry Challenges
  • 6. Total European Revenue Forecasts
    • 1. Revenue Forecasts
  • 7. End-user Segmentation
    • 1. End-user Trends
  • 8. Technology Trends
    • 1. Technology Trends
  • 9. Competitive Landscape
    • 1. Competitive Structure
  • 10. Funding Landscape-Germany
    • 1. Funding Landscape
  • 11. Funding Landscape -United Kingdom
    • 1. Funding Scenario
• 4. Protein Separation Technology
  • 1. Introduction
    • 1. Background
  • 2. Market Engineering Measurements
    • 1. Market Engineering Measurements
  • 3. Revenue Forecasts
    • 1. Revenue Forecasts
• 5. Protein Identification Technology
  • 1. Background
    • 1. Overview
  • 2. Market Engineering Measurements
    • 1. Market Engineering Measurements
  • 3. Revenue Forecasts
    • 1. Revenue Forecasts
• 6. Strategic Recommendations
  • 1. Strategic Recommendations
    • 1. Possible Strategies
• 7. DSD for Proteomics
  • 1. Private Investment for Biotechnology
    • 1. Private Investment in Biotechnology
  • 2. Pharmaceutical R&D Expenditure
    • 1. Pharmaceutical R&D Expenditure
  • 3. Biotech Companies and Number of Employees
    • 1. Biotech Companies
    • 2. Number of Employees
  • 4. Pharmaceutical R&D Expenditure as a percentage of the Pharmaceutical Market
    • 1. Pharmaceutical R&D Expenditure as a Percent of Pharmaceutical Market
• 8. Database of key Industry Participants(DKIP)
  • 1. Database of Key Industry Participants
    • 1. Database of Key Industry Participants